☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Reduce
BridgeBio and Origin's Nulibry (fosdenopterin) Receives the US FDA's Approval as the First Therapy to Reduce the Risk of Mortality...
March 1, 2021
NightWare Receives the US FDA's Approval for the First Medical Device to Stop NightMAres Related to PTSD
November 11, 2020
Merck and Bayer Receive the US FDA's Priority Review for Vericiguat to Reduce the Risk of CV Death in Patients with Symptomatic Ch...
July 16, 2020
Baysient to Release iDose Software Technology Platform 1.0 to Reduce the Biosimilar Cost in Market
February 28, 2020
Eli Lilly's Trulicity (dulaglutide) Receives the US FDA's Approval to Reduce MACE in T2D Adults
February 24, 2020
Astellas Reports Results of Mirabegron in P-IV PLUS Study to Reduce Overactive Bladder Symptoms in Men
May 6, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.